ELISA/assay

KRIBIOLISA™ Efalizumab (RAPTIVA) ELISA

KBI1286

1 x 96 wells

1050 USD

KRIBIOLISA™ Efalizumab (RAPTIVA) ELISA

ELISA

1 x 96 wells

1050 USD

Efalizumab (RAPTIVA) ELISA for quantitative determination of Efalizumab (RAPTIVA) in human serum, plasma Krishgen PK kits, developed using the innovator drug as calibrator, are used for the quantitation of serum protein drug levels, and can be used for biosimilar and generics research as well. About the kit: - Uses anti-idiotypic antibodies sourced from our vendor partner in the US, which ensures higher specificity, and low cross reactivity. - Recovery rates are between 85 - 115% - Ready to use with a standard protocol with break-apart pre-coated wells - Validated as per US FDA guidelines for Bioassays - Optimized for matrix effects to ensure higher sensitivity. - Shelf life: 1 year

Human

Efalizumab is an anti-CD11a antibody that was used in the past as a very effective treatment for psoriasis. Efalizumab binding blocks the binding of LFA-1 to ICAM-1 via steric hindrance between its light chain and ICAM1 domain 2 and thus inhibits the activities of LFA-1. These results have important implications for the development of improved antibodies and new therapeutic strategies for the treatment of autoimmune diseases. In 2009, Efalizumab was voluntarily recalled from the market for the association of Raptiva with an increased risk of progressive multifocal leukoencephalopathy (PML), a rare and usually fatal disease of the central nervous system.

This ELISA kit comes with a pre-coated plate, concentrated or lyophilized standards, wash solution, subtrate, stop solution and all the required diluents. For the exact contents of the kit, please refer to the datasheet / IFU.

2-8 Deg C

0 ng/ml - 640 ng/ml

7.5 ng/ml

IL-23A Protein is pre-coated onto microwells. Samples and standards are pipetted into microwells. Efalizumab present in the sample is bound by the protein. Then, an Anti-Human IgG conjugated to HRP is pipetted and incubated. After washing microwells, in order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Efalizumab in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.

Efalizumab

RUO

2-8 degrees C